A rational approach to drug therapy of type 2 diabetes mellitus

Drugs

Volumn 60, Issue 1, 2000, Pages 95-113

  Chehade, Joe M ^a   Mooradian, Arshag D ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ACETOHEXAMIDE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE; CHLORPROPAMIDE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLIQUIDONE; GLUCAGON LIKE PEPTIDE 1; INSULIN; INSULIN ASPART; INSULIN GLARGINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; METFORMIN; MIGLITOL; PIOGLITAZONE; PRAMLINTIDE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA; THIAZOLIDINE DERIVATIVE; TOLAZAMIDE; TOLBUTAMIDE; TROGLITAZONE; UNINDEXED DRUG;

ANEMIA; CLINICAL TRIAL; DIET THERAPY; EXERCISE; FLATULENCE; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPOGLYCEMIA; INSULIN SENSITIVITY; INSULIN TREATMENT; LACTIC ACIDOSIS; LIVER TOXICITY; NAUSEA; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL ACTIVITY; REVIEW; STOMACH BYPASS; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 0033901387     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200060010-00006     Document Type: Review

References (174)

1. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults: The third national health and nutrition examination survey, 1988-1994
2. Prevalence and incidence of non-insulin-dependent diabetes
3. Drug therapy of non-insulin-dependent diabetes mellitus in the elderly
4. Pathophysiology of type 2 diabetes and modes of action of therapeutic interventions
5. Sulfonylureas
6. Pharmacologic therapy for type 2 diabetes mellitus
7. Therapeutic approaches to type 2 diabetes
8. Drug treatment of non-insulin dependent diabetes mellitus in the 1990s: Achievement and future developments
9. Oral anti-diabetic agents: A guide to selection
10. The association of girth measurements with disease in 32,856 women
11. Epidemiology and genetics of diabetes mellitus
12. Long-term effects of modest weight loss in type II diabetic patients
13. Relationship of body fat distribution to blood pressure, carbohydrate tolerance and plasma lipids in healthy obese women
14. Relationship of fat distribution to glucose tolerance: Results of computer tomography in male participants of the normative aging study
15. The relationship between subsets of anthropometric upper versus lower body measurements and coronary heart disease risk in middle-aged men: The Paris prospective study I
16. Regional adiposity patterns in relation to lipids, lipoprotein cholesterol, and lipoprotein subfraction mass in men
17. Regional obesity
18. Role of orlistat in the treatment of obese patients with type 2 diabetes: A 1-year randomized double-blind study
19. Effects of caloric restriction and weight loss on glycemic control, insulin release and resistance, and atherosclerotic risk in obese patients with type II diabetes mellitus
20. Loss of abdominal fat and metabolic response to exercise training in obese women
21. Effect of weight loss on mechanisms of hyperglycemia in obese non-insulin-dependent diabetes mellitus
22. Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus
23. Exercise and physical training: Effects on insulin sensitivity and glucose metabolism
24. Improvement in glucose tolerance after one week of exercise in patients with mild NIDDM
25. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise
26. Dietary therapy in diabetes mellitus: Is there a single best diet?
27. Nutritional recommendations and principles for people with diabetes mellitus
28. Methods for voluntary weight Loss and Control
29. Current concepts in the pharmacologic management of obesity
30. Hyperinsulinemia as an independent risk factor for ischemic heart disease
31. Relationships between plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population
32. Do non-insulin-dependent diabetes mellitus and cardiovascular disease share common antecedents?
33. Hyperinsulinaemia as a predictor of coronary heart disease mortality in a healthy population: The Paris Prospective Study, 15-year follow-up
34. Insulin and atheroma: 20-years perspective
35. Plasma insulin as coronary heart disease risk factor: Relationship to other risk factors and predictive value during 9 1/2 -year follow-up of the Helsinki Policemen Study Population
36. Effect of insulin therapy on macrovascular risk factors in type 2 diabetes
37. Insulin and cardiovascular disease: Paris prospective study
38. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations
39. British Regional Heart Study: Cardiovascular risk factors in middle-aged men in 24 towns
40. Risk factors for ischaemic heart disease: Is it time to measure insulin?
41. Effects of hypoglycemic agents on vascular complications in patients with adult onset diabetes: VII. Mortality and selected nonfatal events with insulin treatment
42. Exogenous insulin administration and cardiovascular risk in non-insulin-dependent and insulin-dependent diabetes mellitus
43. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
44. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study
45. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI Study): Effects on mortality at 1 year
46. Glycometabolic state at admission: Important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: Long-term results from the Diabetes and Insulin-Glucose infusion in Acute Myocardial Infarction (DIGAMI) study
47. Cardiovascular events and correlates in the veterans affairs diabetes feasibility trial
48. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
49. Repaglinide
50. In vivo metformin treatment ameliorates insulin resistance: Evidence of potentiation of insulin-induced translocation and increased functional activity of glucose transporters in obese (fa/fa)Zucker rat adipocytes
51. Metformin
52. Effect of metformin on treatment on insulin action in diabetic rats: In vivo and in vitro correlations
53. Cellular mechanisms of action of metformin
54. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus
55. An antidiabetic, thiazolidinedione, is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ)
56. Thiazolidinediones in the treatment of insulin resistance and type II diabetes
57. Metabolic effects of new oral hypoglycemic agent troglitazone in NIDDM subjects
58. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone
59. Troglitazone: A review of its use in the management of type 2 diabetes mellitus
60. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus
61. Pharmacological modification of digestion and absorption
62. Acarbose: A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential
63. Principles of insulin therapy
64. Factors influencing the absorption, serum insulin concentration and blood glucose responses after injections of regular insulin and various mixtures
65. Clinical pharmacology of human insulin
66. The effects of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
67. Rationale for the use of insulin therapy alone as the pharmacological treatment of type 2 diabetes
68. Overview of current therapeutic options in type 2 diabetes: Rationale for combining oral agents with insulin therapy
69. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus: A randomized controlled trial
70. The effects of metformin in poorly controlled insulin-treated type 2 diabetes mellitus
71. Troglitazone use in insulin treated type 2 diabetic patients
72. [Lys(B28), Pro(B29)]-human insulin: A rapidly absorbed analogue of human insulin
73. Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin
74. Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28), Pro(B29)] in IDDM
75. Insulin lispro
76. Prandial glycemia after a carbohydrate-rich meal in type I diabetic patients: Using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin
77. Pre-meal insulin analogue insulin lispro vs. Humulin(R) insulin treatment in young subjects with type I diabetes
78. Improved post-prandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic B-cell function
79. Reduction of postprandial and frequency of hypoglycemia in IDDM patients on insulin analog treatment
80. Mealtime treatment with insulin analog improves post prandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus
81. Insulin lispro in CSII: Results of a double-blind crossover study
82. Human insulin analogue (Lys[B28], Pro[B29]): The ideal pump insulin?
83. Improvement of HbA(1C) and blood glucose stability in IDDM patients treated with Lispro insulin analog in external pumps
84. Use of the short-acting insulin analogue lispro in intensive treatment of type 1 diabetes mellitus: Importance of appropriate replacement of basal insulin and time-interval injection-meal
85. Drug therapy of postprandial hyperglycemia
86. Improved glycemic control with insulin aspart. A multicenter, randomized double-blind crossover trial in type 1 diabetic patients: UK Insulin Aspart Study Group
87. Effects of the rapid acting insulin analogue insulin aspart on post prandial glycemic excursions compared to human soluble insulin actrapid given immediately or 30 minutes before a meal in insulin treated type 2 diabetes patients
88. Variability of the metabolic effect of soluble insulin and the rapid acting insulin analog insulin aspart
89. Improved post prandial glycemic control during treatment with Humalog Mix 25, a novel protamine-based insulin lispro formulation
90. Long-acting insulin analogs
91. Time-action profile of the long-acting insulin analogue HOE 901
92. Effects of amylin and the amylin agonist pramlintide on glucose metabolism
93. Amylin concentrations and glucose control
94. Structure and biology of amylin
95. Molecular physiology of amylin
96. Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: Results of a multicenter trial
97. Reduction of post-prandial hyperglycemia in subjects with IDDM by intravenous infusion of AC137, a human amylin analogue
98. Pramlintide: A human amylin analogue reduced post prandial plasma glucose, insulin and C peptide concentrations in patients with type 2 diabetes
99. The pramlintide in type 2 diabetes group: Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin
100. Pramlintide therapy in the treatment of insulin requiring type 2 diabetes: Results of a 1-year placebo-controlled trial
101. GLP-1 in NIDDM
102. Gastric emptying, glucose responses, and insulin secretion after liquid test meal: Effects of exogenous glucagon-like peptide-1 (GLP-1) - (7-36) amide in type 2 (noninsulin-dependent) diabetic patients
103. GLP-1 tablet in type 2 diabetes in fasting and post prandial conditions
104. Sulfonylureas in NIDDM
105. + channels
106. Sulfonylurea anti-diabetic drugs: An update of their clinical pharmacology and rational therapeutic use
107. Glimepiride, a new once-daily sulfonylurea: A double-blind, placebo-controlled study of NIDDM patients
108. Different effects of glyburide and glipizide on insulin secretion and hepatic glucose production in normal and NIDDM subjects
109. Pharmacokinetics and metabolic effects of glibenclamide and glipizide in type 2 diabetics
110. Secondary failure to treatment with oral antidiabetic agents in non-insulin dependent diabetes
111. Characteristics of non-insulin dependent diabetic patients with secondary failure to oral antidiabetic therapy
112. Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents
113. Sulphonylureas and hypoglycaemia
114. Incidence of severe side effects during therapy with sulfonylureas and biguanides
115. Severe drug-induced hypoglycemia: A review
116. Glibenclamide-associated hypoglycemia: A report of 57 cases
117. Lipoprotein patterns in diet, sulfonylurea and insulin-treated diabetics
118. Relation of high-density-lipoprotein-cholesterol concentration in diabetes mellitus
119. A comparison of the effects of tolazamide and tolbutamide upon blood glucose and serum insulin and lipid levels in diabetic subjects
120. University Group Diabetes Program: A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes
121. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: VI. Supplementary report on non-fatal events in patients treated with tolbutamide
122. The University Group Diabetes Program: A statistician looks at the mortality results
123. A summary of criticism of the findings and conclusions of the University Group Diabetes Program (UGDP) study
124. Controversy over study of diabetes drugs continues for nearly a decade
125. Policy statement: The UGDP controversy
126. Metformin: An update
127. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus
128. Effects of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients
129. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus
130. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects
131. Effect of metformin on insulin-stimulated glucose turnover and insulin binding to receptors in type II diabetes
132. The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients
133. Causes of weight gain during insulin therapy with and without metformin in patients with type 2 diabetes mellitus
134. Diarrhea and metformin in a diabetic clinic
135. Incidence of lactic acidosis in metformin users
136. Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human adipocyte differentiation
137. Effects of troglitazone: A new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy
138. Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone
139. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients
140. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus
141. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus: A randomized double blind placebo controlled trial
142. Troglitazone
143. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives
144. A novel antidiabetic drug, troglitazone: Reason for hope and concern
145. Hepatic dysfunction associated with troglitazone
146. Troglitazone: Anti-hyperglycemic activity and potential role in the treatment of type 2 diabetes
147. Rosiglitazone
148. The effect of acarbose and miglitol (BAY-M-1099) on post-prandial glucose levels following ingestion of various sources of starch by nondiabetic and streptozotocin-induced diabetic rats
149. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone
150. Effect of acarbose on carbohydrate and lipid metabolism in NIDDM patients poorly controlled by sulfonylureas
151. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutaminde-plus acarbose in non-insulin dependent diabetes mellitus
152. Pharmacology of α-glucosidase inhibition
153. The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone
154. Effect of the CHO inhibitor miglitol in sulfonylurea-treated NIDDM patients
155. Chronic treatment of African-American type 2 diabetic patients with α-glucosidase inhibition
156. Long-term titrated dose α-glucosidase inhibition in non-insulin-requiring Hispanic NIDDM patients
157. The absorption and retention of dietary zinc by type 1 diabetic rats are increased by chronic treatment with acarbose
158. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (UKPDS 44)
159. European comparative study of 2 alpha-glucosidase inhibitors: Miglitol and acarbose
160. Metabolic effects of Repaglinide, a new oral hypoglycemic agent in therapy - naive type 2 diabetic
161. Repaglinide vs. glibenclamide: A 14-week efficacy and safety comparison
162. Additional treatment with repaglinide provides significant improvement in glycemic control in NIDDM patients poorly controlled on metformin
163. A new oral hypoglycemic agent, repaglinide minimizes risk of hypoglycemia in well controlled type 2 diabetic patients
164. Pharmacodynamics and dose response of nateglinide in type 2 diabetes
165. Comparison of meal-time glucose regulation by nateglinide and repaglinide in healthy subjects
166. Non-insulin-dependent diabetes mellitus
167. Syndrome of insulin resistance: From patient to gene and back again
168. Non-insulin-dependent diabetes mellitus: A genetically programmed failure of the beta cell to compensate for insulin resistance
169. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
170. Effects of obesity on the response to insulin therapy in non-insulin dependent diabetes mellitus
171. Repaglinide: A viewpoint
172. Diabetes care for older adults
173. Management of diabetes mellitus in the nursing home